Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

Agilent (A) announced its PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification for the use as a Companion Diagnostic to aid in ...

Agilent also secured Class C In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx, a critical assay used in determining patient eligibility for specific cancer therapies.

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.